Vincristine, bleomycin, methotrexate, 5-fluorouracil, and prednisone in metastatic, hormonally unresponsive prostatic adenocarcinoma.
Patients with hormonally unresponsive prostatic adenocarcinoma were subjected to a five-drug chemotherapy program using bleomycin, 5-fluorouracil, methotrexate, vincristine, and prednisone. Analysis of survival curves indicated that deletion of an alkylating agent from this five-drug program reduced survival when patients with equal risk factors were compared. Bleomycin was poorly tolerated by this aged population.